Adolor Corporation

Adolor Corporation is a biopharmaceutical company that specializes in the discovery, development, and commercialization of novel prescription pain management products. The company was founded in 1994 and is headquartered in Exton, Pennsylvania.

History

Adolor Corporation was established in 1994 with a focus on the development of novel analgesics. The company's initial research efforts were directed towards the identification and development of new drugs for the treatment of pain and inflammation. Over the years, Adolor has expanded its research and development efforts to include a broad range of therapeutic areas.

Products

Adolor's flagship product is ENTEREG, a drug approved by the Food and Drug Administration (FDA) for the management of postoperative ileus. ENTEREG works by blocking the effects of opioid medications in the gut, thereby reducing the incidence of postoperative ileus, a condition characterized by a temporary impairment of the bowel's ability to contract and move stool or gas out of the body.

Research and Development

Adolor Corporation has a robust research and development program. The company's R&D efforts are primarily focused on the discovery and development of novel, non-opioid analgesics for the treatment of acute and chronic pain. Adolor's research team utilizes a variety of innovative technologies and approaches to identify and develop new drug candidates.

Acquisition

In 2011, Adolor Corporation was acquired by Cubist Pharmaceuticals, a biopharmaceutical company based in Lexington, Massachusetts. The acquisition was completed in a deal valued at approximately $415 million.

See Also

• Biopharmaceutical
• Analgesic
• Pain management
• Food and Drug Administration
• Cubist Pharmaceuticals